|
2.6 Etiologie - Environnement
|
|
|
|
|
2.7 Etiologie - Obésité
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
Identity inference of genomic data using long-range familial searches [Science]
|
|
|
|
|
|
Using
genomic data of 1.28 million individuals tested with consumer genomics,
we investigated the power of this technique. We project that about 60%
of the searches for individuals of European-descent will result in a
third cousin or closer match, which can allow their identification using
demographic identifiers.
|
|
|
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
For HPV-Positive Women, Test Can Guide Cervical Cancer Screening Follow-Up [NCI]
|
|
|
|
|
|
“This
is a very important study,” said Mark Stoler, M.D., associate director
of Surgical Pathology and Cytopathology at the University of Virginia
School of Medicine. It’s the first study performed in the United States,
Dr. Stoler continued, “that really provides the assurance that [dual
stain] is a better triage test” than the Pap test.
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
Deep Learning Can Help Distinguish Recalled-benign Mammograms from Malignant and Negative Mammograms [AACR]
|
|
|
|
|
|
The
researchers used a total of 14,860 images of 3,715 patients from two
independent mammography datasets, Full-Field Digital Mammography Dataset
(FFDM - 1,303 patients) and Digital Dataset of Screening Mammography
(DDSM - 2,412 patients). They built CNN models and utilized enhanced
model training approaches to investigate six classification scenarios
that would help distinguish images of benign, malignant, and
recalled-benign mammograms.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
|
Resistance to CAR T Cell Therapy [ESMO]
|
|
|
|
|
|
Two
Brief Communication papers published on 1 October 2018 in the Nature
Medicine underline that acquired resistance to CD19-targeted CAR T cell
therapy can occur through mutations in the CD19 gene or after insertion
of a chimeric antigen receptor (CAR) into leukaemia cells, resulting in
the adjacent receptor being masked by the CAR.
|
|
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
Allogene’s IPO Raises $288M for Tests of “Off-the-Shelf” Cell Therapy [Xconomy]
|
|
|
|
|
|
Allogene
has licensed rights to UCART19, a cell therapy that is currently being
tested in two in Phase 1 studies. Allogene bought the U.S. rights to the
therapy from Pfizer, as well as the rights to 16 preclinical CAR-T
therapies Pfizer also controlled. Those, as well as UCART19, originated
with the French-American biotech Cellectis.
|
|
|
|
|
|
|
|
5.6 ESMO
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
ABPI tells MPs Brexit deal on medicines regulation ‘urgently needed’ [PharmaTimes]
|
|
|
|
|
|
Giving
evidence to a commons select committee, Mike Thompson, chief executive
of the Association of the British Pharmaceutical Industry, said firms
are increasing stocks of medicine and duplicating testing in the EU, but
warned that there are situations “completely out of our control, which
can only be fixed by a UK/EU deal on the future of medicines”.
|
|
|
|
|
|
|
6.3 Associations/Fondations
|
|
|
Progress against pancreatic cancer [MIT News]
|
|
|
|
|
|
Jacks
and his colleagues describe the Lustgarten investment as high-risk,
high-reward — an innovation fund to move beyond incremental improvements
at both the bench and the bedside.
|
|
|
|
|
|
|
6.5 Médecines alternatives/complémentaires
|
|
|
|
6.9 Controverses
|
|
|